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A dichotomy between immunologically active and quies-
cent cancer phenotypes has been demonstrated for several
types of cancer. Central to such dichotomy is the master
regulator of the acute inflammatory process interferon
regulatory factor (IRF)-1. Although the relevance of IRF-1
to the immune biology of cancer is emerging, it remains
unknown whether the responsiveness of IRF-1 to immune
cytokines is able to point out different cancer behaviours.
Here, we explored the significance of the IFN-g- and TNF-
a-induced activation of IRF-1 in 15 melanoma cell lines.
We measured IRF-1 activation in 15 melanoma cell lines
at basal level and after treatment with IFN-g, TNF-a and a
combination of both using ImageStream technique
(Amnis Corp). Microarray analysis was applied to compare
transcriptional patterns between cell lines characterised by
high and low IRF-1 activation. Functional interpretation
analysis was performed using the Ingenuity Pathway Ana-
lysis system (IPA) tools 3.0. We observed a strong positive
correlation between IRF-1 activation at basal level and
after IFN-g and TNF-a treatment (r=0.65, p=0.007 and
r=0.66, p=0.007, respectively) suggesting that both the
cytokines have a strong effect in inducing IRF-1 activation.
Given that different cell lines have different amplitude of
response to cytokine stimulation, we next asked whether
the inducibility of IRF-1 by IFN-g and TNF-a was able to
distinguish a parallel different behaviour of cancer cells.
Toward this aim, we measured the difference of nuclear
translocation score between controls and stimulated cells
and further selected 3 cell lines with low and 3 cell lines
with high delta IRF-1 nuclear translocation. Microarray
demonstrated that the 3 cell lines with low and the 3 with
high IRF-1 inducible translocation scores differed in the
expression of 597 annotated transcripts. Functional inter-
pretation analysis showed mTOR and Wnt/b-cathenin as
the top upregulated pathways in the cell lines with low
inducible IRF-1 activation, suggesting that a low IRF-1
inducibility recapitulates a cancer phenotype already
described in literature characterised by poor prognosis. In
conclusion, our findings suggest that the responsiveness of
IRF-1 to IFN-g and TNF-a is able to point out different
cancer phenotypes and support the central role of this
transcription factor in influencing different tumor
behaviours.
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